# Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate Cancer

> **NCT00116142** · PHASE3 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 350 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** Androgen Hormonal Suppression and Radiation
- **DRUG:** Androgen Suppression Therapy and Radiation Therapy

## Key facts

- **NCT ID:** NCT00116142
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06
- **Primary completion:** 2020-06-29
- **Final completion:** 2020-06-29
- **Target enrollment:** 350 (ACTUAL)
- **Last updated:** 2022-01-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00116142

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00116142, "Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate Cancer". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT00116142. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*